文献速递乳腺癌

复发性转移性乳腺癌的特征与转移后生存随时间的变化——一项2001-2016年澳大利亚基于人群的记录链接研究

Characteristics and post-metastasis survival of recurrent metastatic breast cancer over time - An Australian population-based record linkage study, 2001-2016.
PubMed 文献 · Eur J Cancer · 2023-12-02

该研究链接新南威尔士州癌症登记处等数据,分析2001-2002年(C1)和2006-2007年(C2)诊断的非转移性乳腺癌女性中2267例复发性转移性乳腺癌患者。C2队列预后特征更差,但乳腺癌死亡五年概率与C1相似(C2 63% vs C1 65%),在治疗定义的HER2阳性乳腺癌中C2低于C1。

要点

  • C2队列更多接受辅助化疗(38% vs 47%)和芳香化酶抑制剂(52% vs 73%)。
  • 乳腺癌死亡五年概率C1为65%(95%CI 62-68%),C2为63%(95%CI 60-66%)。
  • 治疗定义HER2阳性者五年死亡概率C1为72% vs C2为52%。

核心结论

  • 尽管C2队列预后特征更不利,两队列复发性转移性乳腺癌后的乳腺癌相关生存相似,且在HER2阳性肿瘤女性中改善。
  • 这些发现支持较新治疗对复发性转移性乳腺癌的真实世界获益。

研究设计与样本

  • 基于人群的记录链接研究,链接新南威尔士州癌症登记处、医院行政记录、配发药物和放疗服务数据(2001-2016)。
  • 纳入2001-2002年(C1)和2006-2007年(C2)诊断的非转移性乳腺癌女性,分析2267例复发性转移性乳腺癌患者(C1:1210例,C2:1057例)。

主要发现

  • 与C1相比,C2可及辅助HER2靶向治疗,且更多接受辅助化疗(C1 38% vs C2 47%)和芳香化酶抑制剂(在接受内分泌治疗者中C1 52% vs C2 73%)。
  • 乳腺癌死亡五年概率C1为65%(95%CI 62-68%),C2为63%(95%CI 60-66%)。
  • 初诊时区域性疾病(T4或N+)C1为62%、C2为68%,首次转移时年龄≥70岁C1为27%、C2为31%,二者在C2更常见且预后更差。
  • 治疗定义HER2阳性乳腺癌的乳腺癌死亡五年概率C2低于C1(C1 72%,95%CI 63-79%;C2 52%,95%CI 45-60%)。
  • 仅接受化疗者乳腺癌死亡五年概率C2低于C1(C1 76%,95%CI 69-82;C2 67%,95%CI 59-74%,p=0.01);治疗定义激素受体阳性HER2阴性者C1为60%(95%CI 56-63%)、C2为64%(95%CI 60-68%),未见降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To assess population-level characteristics and post-metastasis survival of people with recurrent metastatic breast cancer (rMBC) during a period when new publicly-subsidised adjuvant and metastatic systemic therapies became available. METHODS: Record linkage study of females in NSW Cancer Registry (NSWCR) diagnosed with non-metastatic breast cancer (BC) in 2001-2002 (C1) and 2006-2007 (C2). We identified first rMBC from NSWCR, administrative hospital records, dispensed medicines and radiotherapy services (2001-2016). We used death registrations to estimate cumulative incidence of BC death. RESULTS: The analysis included 2267 women with rMBC (C1:1210, C2:1057). Compared to C1, C2 had access to adjuvant HER2-targeted therapy and were more likely to have received adjuvant chemotherapy (C1:38%, C2:47%) and aromatase inhibitors (C1:52%, C2:73%, of those dispensed endocrine therapy). Five-year probability of BC death was 65% (95%CI:62-68%) in C1 and 63% (95%CI:60-66%) in C2. Regional disease (T4 or N + ) at initial BC diagnosis (C1:62%, C2:68%), and age ≥ 70 years at first metastasis (C1:27%, C2:31%) were more common in C2 and had poorer prognosis. Five-year probability of BC death was lower in C2 than C1 for treatment-defined HER2-positive BC (C1:72% 95%CI:63-79%; C2:52% 95%CI 45-60%) and those dispensed chemotherapy alone (C1:76% 95%CI:69-82, C2:67% 95%CI:59-74%, p = 0.01), but not treatment-defined hormone receptor-positive HER2-negative BC (C1:60% 95%CI 56-63%, C2:64% 95%CI 60-68%). CONCLUSIONS: Despite less favourable prognostic characteristics in C2, BC-related survival following rMBC was similar between the two cohorts; and improved for women with HER2-positive tumours. These findings support the real-world benefits of newer treatments for rMBC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lord SJ, Kiely BE, O'Connell DL, et al. Characteristics and post-metastasis survival of recurrent metastatic breast cancer over time - An Australian population-based record linkage study, 2001-2016. Eur J Cancer. 2023. PMID: 38061215. doi:10.1016/j.ejca.2023.113468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。